Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Roche Sticking With SMA Despite Terminating Olesoxime

Jun 04 2018

• By Kevin Grogan

SC1806_Broken Light Bulb_686792284_1200.jpg — One project blown, one left for Roche in SMA • Source: Shutterstock

Related Content

Biogen's Spinraza Sales Plateau; The Challenge Is Keeping Up With The Successful Launch

Apr 24 2018

Deal-happy Roche acquires Trophos

Jan 16 2015

Novartis Goes Big On Gene Therapy With $8.7bn AveXis Acquisition

Apr 09 2018

Biogen's SMA Ambitions Run Up Against A New Deep-Pocketed Rival

Apr 09 2018

Related Companies

Roche Holding AG

Biogen, Inc.

Ionis Pharmaceuticals, Inc.

Novartis AG

AveXis, Inc.

PTC Therapeutics, Inc.

Additional Topics

Rare Diseases Clinical Trials Research & Development Neurology BioPharmaceutical

More from Rare Diseases

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window